Downregulation of GLUT3 impairs STYK1/NOK‑mediated metabolic reprogramming and proliferation in NIH‑3T3 cells

Shi,Weiye; Fu,Yu; Wang,Yingze

doi:10.3892/ol.2021.12788

Downregulation of GLUT3 impairs STYK1/NOK‑mediated metabolic reprogramming and proliferation in NIH‑3T3 cells

Authors:
- Weiye Shi
- Yu Fu
- Yingze Wang
View Affiliations

Affiliations: Cell Engineering Laboratory, College of Biological Science and Engineering, Hebei University of Science and Technology, Shijiazhuang, Hebei 050018, P.R. China
Published online on: May 14, 2021 https://doi.org/10.3892/ol.2021.12788
Article Number: 527
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Serine threonine tyrosine kinase 1 (STYK1)/novel oncogene with kinase domain (NOK) has been demonstrated to promote cell carcinogenesis and tumorigenesis, as well as to strengthen cellular aerobic glycolysis, which is considered to be a defining hallmark of cancer. As the carriers of glucose into cells, glucose transporters (GLUTs) are important participants in cellular glucose metabolism and even tumorigenesis. However, to the best of our knowledge, the role of GLUTs in biological events caused by STYK1/NOK has not yet been reported. The present study assessed GLUT3 as a key transporter, and glucose consumption and lactate production assays revealed that downregulation of GLUT3 impaired STYK1/NOK‑induced augmented glucose uptake and lactate production, and RT‑qPCR and western blotting confirmed that GLUT3 knockdown attenuated the STYK1/NOK-induced increase in the expression levels of key enzymes implicated in glycolysis. Furthermore, MTT and Transwell assays demonstrated that STYK1/NOK‑triggered cell proliferation and migration were also markedly decreased following knockdown of GLUT3. To the best of our knowledge, the present study is the first to demonstrate that GLUT3 serves a prominent role in STYK1/NOK‑driven aerobic glycolysis and cell proliferation characteristics. These findings may provide a clue for the investigation of the oncogenic activity of STYK1/NOK and for the identification of potential tumor therapy targets associated with GLUT3.

View Figures

View References

1	Ye X, Ji C, Huang Q, Cheng C, Tang R, Xu J, Zeng L, Dai J, Wu Q, Gu S, et al: Isolation and characterization of a human putative receptor protein kinase cDNA STYK1. Mol Biol Rep. 30:91–96. 2003. View Article : Google Scholar : PubMed/NCBI
2	Liu L, Yu XZ, Li TS, Song LX, Chen PL, Suo TL, Li YH, Wang SD, Chen Y, Ren YM, et al: A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res. 64:3491–3499. 2004. View Article : Google Scholar : PubMed/NCBI
3	Cao Q, Chen M, Li Z, Huang W, Jin Y, Ye X and Tong M: High novel oncogene with kinasedomain (NOK) gene expression is associated with the progression of renal cell carcinoma. Clin Lab. 62:179–186. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chen P, Li WM, Lu Q, Wang J, Yan XL, Zhang ZP and Li XF: Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer. BMC Cancer. 14:4022014. View Article : Google Scholar : PubMed/NCBI
5	Jackson KA, Oprea G, Handy J and Kimbro KS: Aberrant STYK1 expression in ovarian cancer tissues and cell lines. J Ovarian Res. 2:152009. View Article : Google Scholar : PubMed/NCBI
6	Moriai R, Kobayashi D, Amachika T, Tsuji N and Watanabe N: Diagnostic relevance of overexpressed NOK mRNA in breast cancer. Anticancer Res. 26((6c)): 4969–4973. 2006.PubMed/NCBI
7	Orang AV, Safaralizadeh R, Hosseinpour Feizi MA and Somi MH: Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/NOK) mRNA in colorectal cancer. Asian Pac J Cancer Prev. 15:6685–6689. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chung S, Tamura K, Furihata M, Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y and Nakagawa H: Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castrationresistant prostate cancer. Cancer Sci. 100:2109–2114. 2009. View Article : Google Scholar : PubMed/NCBI
9	Shi WY, Yang X, Huang B, Shen WH and Liu L: NOK mediates glycolysis and nuclear PDC associated histone acetylation. Front Biosci (Landmark Ed). 22:1792–1804. 2017. View Article : Google Scholar : PubMed/NCBI
10	Thorens B and Mueckler M: Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 298:E141–E145. 2010. View Article : Google Scholar : PubMed/NCBI
11	Barrona CC, Bilan PJ, Tsakiridis T and Tsiani E: Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 65:124–139. 2016. View Article : Google Scholar : PubMed/NCBI
12	Ganapathy V, Thangaraju M and Prasad PD: Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Ther. 121:29–40. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhao FQ and Keating AF: Functional properties and genomics of glucose transporters. Curr Genomics. 8:113–128. 2007. View Article : Google Scholar : PubMed/NCBI
14	Shi Y, Liu S, Ahmad S and Gao Q: Targeting key Transporters in tumor glycolysis as a novel anticancer strategy. Curr Top Med Chem. 18:454–466. 2018. View Article : Google Scholar : PubMed/NCBI
15	Zhao M and Zhang Z: Glucose transporter regulation in cancer: A profile and the loops. Crit Rev Eukaryot Gene Expr. 26:223–238. 2016. View Article : Google Scholar : PubMed/NCBI
16	Alexandra C and Al-Hasani H: Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch. 472:1273–1298. 2020. View Article : Google Scholar : PubMed/NCBI
17	Reckzeh ES and Waldmann H: Development of glucose transporter (GLUT) inhibitors. European J Org Chem. 2020:2321–2329. 2020. View Article : Google Scholar : PubMed/NCBI
18	Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, Kelleher T, Miles KA, Ell PJ and Keshtgar MR: ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 38:46–52. 2011. View Article : Google Scholar : PubMed/NCBI
19	Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R, et al: Signaling through the phosphatidylinositol 3-Kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. J Biol Chem. 290:17495–17504. 2015. View Article : Google Scholar : PubMed/NCBI
20	Liu H, Ertay A, Peng P, Li J, Liu D, Xiong H, Zou Y, Qiu H, Hancock D, Yuan X, et al: SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity. Mol Oncol. 13:1874–1886. 2019. View Article : Google Scholar : PubMed/NCBI
21	Whiteman EL, Chen JJ and Birnbaum MJ: Platelet-derived growth factor (PDGF) stimulates glucose transport in 3T3-L1 adipocytes overexpressing PDGF receptor by a pathway independent of insulin receptor substrates. Endocrinology. 144:3811–3820. 2003. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zhuo Z, Hu J, Yang X, Chen M, Lei X, Deng L, Yao N, Peng Q, Chen Z, Ye W and Zhang D: Ailanthone inhibits Huh7 cancer cell growth via cell cycle arrest and apoptosis in vitro and in vivo. Sci Rep. 5:161852015. View Article : Google Scholar : PubMed/NCBI
24	Bose S and Le A: Glucose metabolism in cancer. Adv Exp Med Biol. 1063:3–12. 2018. View Article : Google Scholar : PubMed/NCBI
25	Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
26	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
27	Warburg O and Minami S: Versuche an uberlebendem carcinom-gewebe. Klin Wochenschr. 2:776–777. 1923. View Article : Google Scholar
28	Levine AJ and Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, et al: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2:ra732009. View Article : Google Scholar : PubMed/NCBI
30	Ji H, Lee JH, Wang Y, Pang Y, Zhang T, Xia Y, Zhong L, Lyu J and Lu Z: EGFR phosphorylates FAM129B to promote Ras activation. Proc Natl Acad Sci USA. 113:644–649. 2016. View Article : Google Scholar : PubMed/NCBI
31	Li YH, Wang YY, Zhong S, Rong ZL, Ren YM, Li ZY, Zhang SP, Chang ZJ and Liu L: Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. Mol Cells. 27:39–45. 2009. View Article : Google Scholar : PubMed/NCBI
32	Li J, Wu F, Sheng F, Li YJ, Jin D, Ding X and Zhang S: NOK/STYK1 interacts with GSK-3β and mediates Ser9 phosphorylation through activated Akt. FEBS Lett. 586:3787–3792. 2012. View Article : Google Scholar : PubMed/NCBI
33	Huang Z, Ma N, Xiong YL, Wang L, Li WM, Lai YY, Zhang CX, Zhang ZP, Li XF and Zhao JB: Aberrantly high expression of NOK/STYK1 is tightly associated with the activation of the AKT/GSK3β/N-cadherin pathway in non-small cell lung cancer. Onco Targets Ther. 12:10299–10309. 2019. View Article : Google Scholar : PubMed/NCBI
34	Song K, Li M, Xu XJ, Xuan L, Huang GN, Song XL and Liu QF: HIF-1α and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia. Asian Pac J Cancer Prev. 15:1823–1829. 2014. View Article : Google Scholar : PubMed/NCBI
35	Miller DM, Thomas SD, Islam A, Muench D and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res. 18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI
36	Ramos H, Calheiros J, Almeida J, Barcherini V, Santos S, Carvalho ATP, Santos MMM and Saraiva L: SLMP53-1 inhibits tumor cell growth through regulation of glucose metabolism and angiogenesis in a P53-Dependent manner. Int J Mol Sci. 21:5962020. View Article : Google Scholar : PubMed/NCBI